Effects of Nimotuzumab combined with Oxaliplatin and Paclitaxel chemotherapy in treatment of cervical cancer
Objective:To observe effects of Nimotuzumab combined with Oxaliplatin and Paclitaxel chemotherapy in treatment of cervical cancer.Methods:A prospective study was conducted on 68 patients with cervical cancer admitted to this hospital from June 2021 to May 2023.According to the random number table method,they were divided into observation group and control group,34 cases in each group.The control group was treated with Oxaliplatin combined with Paclitaxel chemotherapy,while the observation group was treated with Nimotuzumab on the basis of that of the control group.The disease control rate,the levels of tumor markers[squamous cell carcinoma-associated antigen(SCC),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),tumor specific growth factor(TSGF)]and cancer inducible factors[kallikrein-related peptidase 5(KLK5),doublecortin-like kinase 1(DCLK1),matrix metalloproteinase-9(MMP-9)],and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the observation group was 76.47%,which was higher than 52.94%of the control group,the difference was statistically significant(P＜0.05).After 1 and 3 courses of treatment,the levels of serum SCC,CYFRA21-1,TSGF,KLK5,DCLK1 and MMP-9 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).However,there was no significant difference in the incidence of adverse reactions such as fever,thrombocytopenia,rash,nausea and abnormal liver function between the two groups(P＞0.05).Conclusions:Nimotuzumab combined with Oxaliplatin and Paclitaxel chemotherapy in the treatment of the cervical cancer patients can improve the disease control rate,and reduce the levels of tumor markers and cancer inducible factors.Moreover,it is superior to Oxaliplatin combined with Paclitaxel chemotherapy.
NETL
NSTL
万方数据
